<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210456</url>
  </required_header>
  <id_info>
    <org_study_id>PREKIT-001</org_study_id>
    <nct_id>NCT01210456</nct_id>
  </id_info>
  <brief_title>Efficacy Trial of N-Acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-Induced Acute Kidney Injury</brief_title>
  <acronym>PREKIT</acronym>
  <official_title>The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokushukai Medical Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokushukai Medical Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Contrast-Induced Acute Kidney Injury(CIAKI) was defined as an absolute increase in serum
      creatinine of more than or equal to 0.3mg/dl (≥ 26.4 μmol/l), a percentage increase in serum
      creatinine of more than or equal to 50% (1.5-fold from baseline) within 48 hours of
      intravascular contrast administration in the absence of any alternative causes, or a
      reduction in urine output documented oliguria of less than 0.5 ml/kg per hour for more than
      six hours.

      It is the common cause of new hospital-acquired renal insufficiency. The occurrence of CIAKI
      may be influenced by pre-existing renal insufficiency, diabetic nephropathy, dehydration,
      congestive heart failure, concurrent administration of nephrotoxic drugs, or the dose and
      type of contrast media used. Previous studies have shown the independent effectiveness of
      several agents in preventing CIAKI.

      Even now, hydration is crucial for preventing CIAKI. Since CIAKI is presumed to be caused by
      free radical generation, N-Acetylcysteine, which is a potent free radical scavenger, is shown
      to be effective in preventing nephropathy. At the same time, because free radical formation
      is promoted by an acidic environment, bicarbonate, which alkalinizes renal tubular fluid, has
      been shown to reduce renal involvement.

      These days, some studies have shown that hydration with sodium bicarbonate plus
      N-Acetylcysteine was effective and safe in the prevention of CIAKI. In these studies,
      bicarbonate was used for both alkalinizing renal tubular fluid and hydration. However, if we
      want to do hydration, we can use saline and if we want to alkalinize renal tubular fluid, we
      might use bicarbonate by bolus injection.

      Actually, bicarbonate for hydration is prepared at sterile preparation room in a hospital,
      which is very cumbersome procedure and increase in cost. This is one of the reasons that
      bicarbonate for hydration use does not become common with wide clinical application.

      In past issues, though it differs depending on the level of the renal dysfunction, the
      probability of CIAKI was 8-33% when hydration was administered, 5-15% when hydration and
      N-Acetylcysteine were administered, and 1.8-1.9% when bicarbonate and N-Acetylcysteine were
      administered.

      Thus, we can hypothesize the combination of N-Acetylcysteine and bicarbonate will play a
      complementary role in preventing contrast-induced nephropathy.

      This is the rational for this study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of contrast-induced acute kidney injury</measure>
    <time_frame>within 48 hours</time_frame>
    <description>Contrast-Induced Acute Kidney Injury(CIAKI) was defined as an absolute increase in serum creatinine of more than or equal to 0.3mg/dl (≥ 26.4 μmol/l), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline) within 48 hours of intravascular contrast administration in the absence of any alternative causes, or a reduction in urine output documented oliguria of less than 0.5 ml/kg per hour for more than six hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Requirement of dialysis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of hospitalization and death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">458</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Physiological Saline and N-Acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate</intervention_name>
    <description>All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.
154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.
In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure.</description>
    <arm_group_label>Physiological Saline and N-Acetylcysteine</arm_group_label>
    <arm_group_label>Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  serum creatinine more or equal than 1.1mg/dL

          -  procedures using contrast media

        Exclusion Criteria:

          -  congestive heart failure

          -  serum creatinine less than 1.1mg/dl

          -  allergy to contrast media

          -  preexisting dialysis

          -  emergency catheterization

          -  recent exposure to contrast within 2 days of the study

          -  refuse to entry this study

          -  PTRA

          -  dialysis after procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisuke Hachinohe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapporo Higashi Tokushukai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo City</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Morcos SK. Contrast media-induced nephrotoxicity--questions and answers. Br J Radiol. 1998 Apr;71(844):357-65. Review.</citation>
    <PMID>9659127</PMID>
  </reference>
  <reference>
    <citation>Benko A, Fraser-Hill M, Magner P, Capusten B, Barrett B, Myers A, Owen RJ; Canadian Association of Radiologists. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J. 2007 Apr;58(2):79-87.</citation>
    <PMID>17521052</PMID>
  </reference>
  <reference>
    <citation>Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983 Feb;74(2):243-8.</citation>
    <PMID>6824004</PMID>
  </reference>
  <reference>
    <citation>Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602-13. Review.</citation>
    <PMID>10525875</PMID>
  </reference>
  <reference>
    <citation>Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.</citation>
    <PMID>17331245</PMID>
  </reference>
  <reference>
    <citation>Briguori C, Tavano D, Colombo A. Contrast agent--associated nephrotoxicity. Prog Cardiovasc Dis. 2003 May-Jun;45(6):493-503. Review.</citation>
    <PMID>12800130</PMID>
  </reference>
  <reference>
    <citation>Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002 May 14;105(19):2259-64.</citation>
    <PMID>12010907</PMID>
  </reference>
  <reference>
    <citation>Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, Mintz GS, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003 Jan;15(1):18-22.</citation>
    <PMID>12499523</PMID>
  </reference>
  <reference>
    <citation>Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006 Jun 29;354(26):2773-82.</citation>
    <PMID>16807414</PMID>
  </reference>
  <reference>
    <citation>Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005 Aug;20(8):1542-50. Review.</citation>
    <PMID>16033768</PMID>
  </reference>
  <reference>
    <citation>Goss RJ. Photoperiodic control of antler cycles in deer. III. Decreasing versus increasing day lengths. J Exp Zool. 1976 Sep;197(3):307-12.</citation>
    <PMID>965912</PMID>
  </reference>
  <reference>
    <citation>Nazarko L. Working parents: a woman's rightful place. Nurs Stand. 1992 May 6-12;6(33):46.</citation>
    <PMID>1591186</PMID>
  </reference>
  <reference>
    <citation>Itoh Y, Yano T, Sendo T, Oishi R. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci. 2005 Apr;97(4):473-88. Epub 2005 Apr 9. Review.</citation>
    <PMID>15821342</PMID>
  </reference>
  <reference>
    <citation>Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc. 2004 Feb;79(2):211-9. Review. Erratum in: Mayo Clin Proc. 2004 Mar;79(3):432. Dosage error in article text.</citation>
    <PMID>14959916</PMID>
  </reference>
  <reference>
    <citation>Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004 Feb;25(3):212-8. Review.</citation>
    <PMID>14972421</PMID>
  </reference>
  <reference>
    <citation>Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002 Oct 16;40(8):1383-8.</citation>
    <PMID>12392825</PMID>
  </reference>
  <reference>
    <citation>Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol. 1981 May;136(5):859-61.</citation>
    <PMID>6784516</PMID>
  </reference>
  <reference>
    <citation>Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008 Feb 19;148(4):284-94. Erratum in: Ann Intern Med. 2008 Aug 5;149(3):219.</citation>
    <PMID>18283206</PMID>
  </reference>
  <reference>
    <citation>Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003 Feb 5;289(5):553-8.</citation>
    <PMID>12578487</PMID>
  </reference>
  <reference>
    <citation>Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002 Jul 17;40(2):298-303.</citation>
    <PMID>12106935</PMID>
  </reference>
  <reference>
    <citation>Fishbane S, Durham JH, Marzo K, Rudnick M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol. 2004 Feb;15(2):251-60. Review.</citation>
    <PMID>14747371</PMID>
  </reference>
  <reference>
    <citation>Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000 Jul 20;343(3):180-4.</citation>
    <PMID>10900277</PMID>
  </reference>
  <reference>
    <citation>Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328-34.</citation>
    <PMID>15150204</PMID>
  </reference>
  <reference>
    <citation>Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007 Mar 27;49(12):1283-8. Epub 2007 Mar 12.</citation>
    <PMID>17394959</PMID>
  </reference>
  <reference>
    <citation>Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007 Mar 13;115(10):1211-7. Epub 2007 Feb 19.</citation>
    <PMID>17309916</PMID>
  </reference>
  <reference>
    <citation>McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997 Nov;103(5):368-75.</citation>
    <PMID>9375704</PMID>
  </reference>
  <reference>
    <citation>Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004 Feb;15(2):407-10.</citation>
    <PMID>14747387</PMID>
  </reference>
  <reference>
    <citation>Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995 Jan;47(1):312-8.</citation>
    <PMID>7731163</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>September 13, 2014</last_update_submitted>
  <last_update_submitted_qc>September 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokushukai Medical Group</investigator_affiliation>
    <investigator_full_name>Daisuke Hachinohe</investigator_full_name>
    <investigator_title>Sapporo Higashi Tokushukai Hospital</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Contrast Media</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>Bicarbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

